

# Gynecology Oncology (GynOnc) Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart

## OVARIAN/ENDOMETRIAL

**UCI 24-146**

REGN5668 + REGN4018 or Cemiplimab  
Coord: Jiana Ejbara  
Accrual: 0/5

## MUTATIONS

**UCI 22-78**

KSQ-4279 +/- Olaparib or Carboplatin  
Targeting deleterious mutation (germline  
or somatic)  
Coord: Jiana Ejbara  
Accrual: 1/5

**UCI 23-186**

Long-term safety and efficacy of  
Pembrolizumab  
Coord: Jiana Ejbara  
Accrual: 1/8

**UCI 24-144**

SCG142 T Cell Receptor  
Targeting HPV16/HPV52  
Coord: Jiana Ejbara  
Accrual: 0/5

## PLATINUM-RESISTANT RECURRENCE

>3L

### GOG-3076

Platinum Doublet + Bevacizumab +/-OlviVec  
 Coord: Jiana Ejbara  
 Accrual: 2/5

## PLATINUM-SENSITIVE RECURRENCE

FRa + and >1L

### GOG-3078

Mirvetuximab Soravtansine  
 Coord: Jiana Ejbara  
 Accrual: 0/5

## OVARIAN CANCER

### UCI 21-190

Assessing the Predictive Capability of Circulating  
Tumor DNA as a Screening Tool for Ovarian  
Cancer

ctDNA

Coord: Jiana Ejbara

Accrual: 2/36